Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica has appointed Lucinda Crabtree as its new Chief Financial Officer, leveraging her extensive experience in finance and biopharmaceuticals to bolster the company’s growth in cell and gene therapy manufacturing. Dr. Frank Mathias, CEO, expressed confidence in her ability to contribute to Oxford Biomedica’s international expansion. Crabtree is enthusiastic about joining the company and supporting its mission to deliver transformative therapies to patients.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
